

Pharmacy Benefact

A BULLETIN FOR PHARMACY SERVICE PROVIDERS FROM ALBERTA BLUE CROSS

Number 488 • October 2014

Removal of temporary benefits from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Apo-Diazepam 5 mg Tablet (DIN 00362158), manufactured by Apotex Inc., pms-Diazepam 5 mg Tablet (DIN 02247491), manufactured by Pharmascience Inc., and Valium 5 mg Tablet (DIN 00013285), manufactured by Hoffmann-La Roche Limited, were added as temporary benefits for the Alberta Drug Benefit List (ADBL) as of August 7, 2014 and September 12, 2014 respectively.

Apotex Inc. has advised Alberta Blue Cross that the shortage of Apo-Diazepam 5 mg Tablet (DIN 00362158) has been resolved.

As a result, pms-Diazepam 5 mg Tablet (DIN 02247491) and Valium 5 mg Tablet (DIN 00013285) will no longer be considered as temporary benefits for the ADBL after November 19, 2014.

Due to the shortages of pms-Ipratropium 0.03% Nasal Spray (DIN 02239627), manufactured by Pharmascience Inc., and Atrovent 0.03% Nasal Spray (DIN 02163705), manufactured by Boehringer Ingelheim (Canada) Ltd., Atrovent 0.06% Nasal Spray (DIN 02163713) manufactured by Boehringer Ingelheim (Canada) Ltd, was added as a temporary benefit for the Alberta Drug Benefit List (ADBL) as of February 25, 2014.

Pharmascience Inc. and Boehringer Ingelheim (Canada) Ltd. have advised Alberta Blue Cross that the shortages of pms-Ipratropium 0.03% Nasal Spray (DIN 02239627) and Atrovent 0.03% Nasal Spray (DIN 02163705) have been resolved.

As a result, Atrovent 0.06% Nasal Spray (DIN 02163713) will no longer be considered a temporary benefit for the ADBL after November 19, 2014.

Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Pharmascience Inc. and Boehringer Ingelheim (Canada) Ltd., that the shortages of pms-Ipratropium 0.03% Nasal Spray (DIN 02239627) and Atrovent 0.03% Nasal Spray (DIN 02163705) have been resolved. Due to the long-term nature of these shortages, a transition period will be applied and as a result, the LCA price policy will be reapplied to the following grouping **effective November 19, 2014**.

IPRATROPIUM BROMIDE

0.03 % NASAL SPRAY

00002239627	PMS-IPRATROPIUM	PMS	\$ 0.7565
00002163705	ATROVENT	BOE	\$ 0.9930

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations call centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)



®The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. ABC 82320.488 2014/10